

SUJITH KALMADI, M.D.

Medical Oncologist & Hematologist · Chief Medical Officer

Ironwood Cancer & Research Centers · 695 S. Dobson Road, Chandler, Arizona 85224 · Office: (480) 821-2838 ·
Fax: (480) 821-9444 · Email: skalmadi@ironwoodcrc.com

I. CLINICAL EXPERIENCE

2019 – Present

Chief Medical Officer

Ironwood Cancer & Research Centers — Chandler, Arizona
Group of 110 multispecialty oncology providers; ~650 employees

2008 – Present

Hematologist and Medical Oncologist

Ironwood Cancer & Research Centers — Chandler, Arizona

2023 – Present

Clinical Assistant Professor

University of Arizona College of Medicine — Phoenix, Arizona

2011 – Present

Clinical Assistant Professor

Midwestern University, Arizona College of Osteopathic Medicine
Glendale, Arizona

2007 – 2008

Clinical Assistant Professor

Baylor Medical College — Methodist Hospital / St. Luke's Hospital
Texas Oncology / US Oncology — Houston, Texas

2006 – 2007

Associate Staff Physician

Solid Tumor, Hematologic Oncology & Blood Disorders
Taussig Cancer Center, Cleveland Clinic — Cleveland, Ohio

2003 – 2006

Fellow — Hematology-Oncology

Taussig Cancer Center, Cleveland Clinic — Cleveland, Ohio

2002 – 2003

Chairman, Department of Medicine

Putnam Hospital — Palatka, Florida

1999 – 2003

Staff Physician

Putnam Hospital — Palatka, Florida

II. POST-GRADUATE EDUCATION

2003 – 2006

Fellowship in Hematology-Oncology

Cleveland Clinic — Cleveland, Ohio

1995 – 1999

Residency in Medicine-Pediatrics

Cleveland Clinic Foundation — Cleveland, Ohio

1994 – 1995

Internship

Henry Ford Hospital — Detroit, Michigan

III. EDUCATION

1993

M.B.B.S.

Kasturba Medical College — Mangalore, India

1987

P.U.C.

Mahatma Gandhi Memorial College — Udupi, India

IV. CERTIFICATION & LICENSURE

A. Board Certifications

Board	Certified	Valid Through	Certificate #
Medical Oncology	11/2006	2036	188865
Hematology	11/2007	2037	188865
Internal Medicine	11/1999	2019	188865
USMLE	March 1994	—	04975520

B. Medical Licensure

State	Date Issued	License #	Status	Expiration
Arizona	4/4/2008	38208	Active (Permanent)	—
Texas	11/30/2007	M8068	Expired	—
Ohio	4/29/1999	35-07-2739	Expired	—
Florida	5/8/1999	ME 77981	Expired	—

V. PROFESSIONAL AFFILIATIONS

1999 – Present

Member, American College of Physicians

2003 – Present

Member, American Society of Clinical Oncology (ASCO)

2003 – Present

Member, American Society of Hematology (ASH)

2005 – 2008

Member, Information Technology Committee

American Society of Clinical Oncology

2007 – 2008

Member, Thoracic Oncology Research Committee

Southwest Oncology Group (SWOG)

2007 – 2008

Member, Gastrointestinal Oncology Research Committee

Southwest Oncology Group (SWOG)

2002 – 2003

Chairman, Department of Medicine

Putnam Medical Center — Palatka, Florida

2002 – 2003

Chairman, Medical Quality Assurance Committee

Putnam Medical Center — Palatka, Florida

2001 – 2003

Chairman, Total Quality Improvement Committee

Family Medical Center — Palatka, Florida

1988

Treasurer, Anatomy Club

Kasturba Medical College

1985

President, Students' Council

Christian High School — Udupi, India

VI. CLINICAL RESEARCH EXPERIENCE

Principal Investigator on multiple Phase 2 and Phase 3 clinical trials at Ironwood Cancer and Research Centers, Arizona (2009–present). Protocols participated in available on request.

During work at Baylor College of Medicine, contributed to thoracic and gastrointestinal malignancies research within the US Oncology Research Network.

During tenure at Cleveland Clinic (Taussig Cancer Center), served as Principal Investigator on 9 clinical trials (3 investigator-initiated, 6 industry-sponsored) in thoracic and gastrointestinal malignancies.

VII. TEACHING ACTIVITIES

Current

Clinical Instructor — Midwestern University College of Osteopathic Medicine, Glendale, Arizona

Clinical Instructor — University of Arizona College of Medicine, Phoenix, Arizona

Previous

Cleveland Clinic Foundation (Taussig Cancer Center): Didactic teaching conferences and rounds with medical students, residents, and fellows in hematology and medical oncology. Focus on thoracic and gastrointestinal malignancies.

Baylor College of Medicine / St. Luke's Hospital: Clinical teaching of hematology-oncology fellows, internal medicine residents, and medical students.

Methodist Hospital: Educational conference presentations and clinical teaching with internal medicine residents.

VIII. OTHER PROFESSIONAL ACTIVITIES

2007

Reviewer — American Board of Internal Medicine

Medical Oncology Subspecialty Examination

2005

Reviewer — Cancer (journal)

2005

Reviewer — Journal of Clinical Oncology

IX. HONORS & AWARDS

2007

Outstanding Teacher of the Year Award

Hematology-Oncology Fellowship Program, Taussig Cancer Center, Cleveland Clinic

2003

Amgen Fellow of the Year Fellowship Grant Award

1994

USMLE — Top 10th Percentile

All three steps passed in the top decile

1993

First Class — All Medical School Examinations

Kasturba Medical College

1985

National Talent Search Scholarship (8 Years)

National Council of Educational Research and Training of India (NCERT)

X. BIBLIOGRAPHY

A. Peer-Reviewed Journal Publications

1. Leal T, Kotecha R, Ramlau R, Zhang L, Milanowski J, Cobo M, Roubec J, Petruzella L, Havel L, Kalmadi S, et al. (LUNAR Study Investigators). Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. *Lancet Oncol.* 2023 Sep;24(9):1002–1017.
2. Anadkat MJ, Lacouture M, Friedman A, Horne ZD, Jung J, Kaffenberger B, Kalmadi S, Ovington L, Kotecha R, Abdullah HI, Grosso F. Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region. *Front Oncol.* 2022;12:975473.
3. Slingluff CL, Lewis KD, Andbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, et al. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in

patients with post-resection melanoma at high risk of recurrence. *J Immunother Cancer*. 2021 Oct;9(10):e003272.

4. Ferrarotto R, Anderson I, Medgyasszay B, García-Campelo MR, Edenfield W, Feinstein TM, Johnson JM, Kalmadi S, Lammers PE, Sanchez-Hernandez A, Pritchett Y, Morris SR, Malik RK, Csósz T. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: pooled analysis of three randomized phase 2 trials. *Cancer Med*. 2021 Sep;10(17):5748–5756.
5. Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S, Gradishar W, Kim SB, Haley B, Ryvo L, Dai MS, Milovanov V, Alarcón J, Kalmadi SR, Cronemberger E, Souza C, Landeiro L, Bose R, Bebchuk J, Kabbinar FF, Bryce R, Keyvanjah K, Brufsky AM. Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial. *Oncologist*. 2021;26(8):e1327–e1338.
6. Moy B, Oliveira M, Saura C, Gradishar W, Kim SB, Brufsky A, Hurvitz SA, Ryvo L, Fagnani D, Kalmadi S, Silverman P, Delaloge S, Alarcon J, Kwong A, Lee KS, Ang PCS, Ow SGW, Chu SC, Bryce R, Keyvanjah K, Bebchuk J, Zhang B, Oestreicher N, Bose R, Chan N. Neratinib plus capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens. *Breast Cancer Res Treat*. 2021;188(1):63–73.
7. Turner et al. (Paloma Study Group). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-8): an open-label randomized controlled phase 3 trial. *Lancet Oncology*. 2015 Aug;16(8):897–907. [Collaborator]
8. Soria et al. (LUX-Lung 8 Investigators). Palbociclib in hormone receptor-positive advanced breast cancer. *N Engl J Med*. 2015 Jul 16;373(3):209–19. [Collaborator]
9. Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single institution experience. *Eur J Surg Oncol*. 2011 Sep;37(9).
10. Bravo EL, Kalmadi SR, Gill I. Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. *Horm Metab Res*. 2009 Sep;41(9):703–6.
11. Kalmadi S, Raghavan D. Evolving perspectives of the role of novel agents in androgen-independent prostate cancer. *Indian J Urol*. 2008 Jul;24(3):303–8.
12. Kalmadi S, Rankin C, Kraut M, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). *Lung Cancer*. 2008 May;60(2):259–263.
13. Almhanna K, Kalmadi S, Pelley R, Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach? *Oncology*. 2007 Aug;21(9). [Review]
14. Kalmadi S, Baz R, Mahindra A. Lenalidomide: the emerging role of a novel targeted agent in malignancies. *Drugs Today (Barc)*. 2007 Feb;43(2):85–95. [Review]
15. Kalmadi S, Tiu R, Lowe C, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirement in patients with thrombocytopenic hemorrhage. *Cancer*. 2006;107(1):136–140.
16. Kalmadi S, Davis M, Dowlati A, et al. Phase I trial of three-weekly docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors. *Invest New Drugs*. 2006.
17. Kalmadi S, McNeill G, Davis M, et al. Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. *Med Oncol*. 2006;23(3).
18. Kalmadi S, Hussein M. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. *Acta Haematol*. 2006;116:1–7. [Review]
19. Kalmadi S. New biology of lung cancer: prognostic factors and therapeutic impact. *Mol Oncol Rep*. 2006. [Review]
20. Gordon S, LaRosa S, Kalmadi S, et al. Should prophylaxis for *Pneumocystis carinii* pneumonia in solid organ transplants ever be discontinued? *Clin Infect Dis*. 1999;28(2):240–6.

B. Book Chapters

1. Kalmadi S, Zhou M, Novick A, Bukowski R. Uncommon tumors of the kidney. In: *Textbook of Uncommon Cancers*, 3rd ed. John Wiley and Sons, 2005.
2. Kalmadi S, Raghavan D. Fundamentals of cancer treatment: effects of chemotherapy on neoplastic cells. In: *Cancer in the Spine: Comprehensive Care for Spinal Column Tumors*. Humana Press, 2005.

C. Selected Abstracts

1. Nabong C, Chang M, Kalmadi S, Ortiz-Cruz K, Chiu V, Batra A, Klein L, Ho E, Hernandez E, Chan T, Vaidya R, Di Como J, Ramanathan RK, Mendonca S. Pembrolizumab added to neoadjuvant chemotherapy for triple negative breast cancer in a community practice setting: real world evidence for the effectiveness of the KN-522 regimen. San Antonio Breast Cancer Symposium 2024; Dec 10–13; San Antonio, TX. Clin Cancer Res. 2025;31(12 Suppl):Abstract P2-08-05.
2. Leal T, Kotecha R, Ramlau R, Zhang L, Milanowski J, Cobo-Dols M, Roubec J, Petruzelka LB, Havel L, Kalmadi SR, et al. (LUNAR Study Investigators). Tumor Treating Field (TTFIELDS) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study. J Clin Oncol. 2023;41(17_suppl):LBA9005. 2023 ASCO Annual Meeting.
3. Rao Kalmadi N, Brown A, Sharma M, Shtivelband M, Rifkind J, Kalmadi S, Bagai R, Ho E, Clark P, Kellogg C, Khanuja P. Impact of gene expression profile testing for lymph node positive (LN+), hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer (BC) patients. San Antonio Breast Cancer Symposium 2021; Dec 7–10; San Antonio, TX. Cancer Res. 2022;82(4 Suppl):Abstract P1-08-18.
4. Almhanna K, Kim R, Kalmadi S, et al. Analysis of 140 cases with biliary tract cancer. 2008 ASCO GI Symposium.
5. Lazaryan A, Almhanna K, Elson P, Kalmadi S, et al. Factors associated with tumor recurrence and 5-year postoperative survival in ampullary carcinoma: Cleveland Clinic experience. 2008 ASCO GI Symposium.
6. Tsao RE, Almhanna K, Lazaryan A, Kalmadi S, et al. Adjuvant radiation plus chemotherapy for resectable pancreatic adenocarcinoma and survival: the Cleveland Clinic experience. ASCO Annual Meeting.
7. Almhanna K, Golshayan A, Sands M, Kalmadi S, et al. Response to transarterial chemoembolization prior to liver transplantation or hepatic resection in hepatocellular carcinoma. 2007 ASCO Annual Meeting. Abstract #15114.
8. Kalmadi S, Pelley R, Kay E, et al. Nigro regimen treatment of squamous cell cancer of the anus. 2007 ASCO Annual Meeting. Abstract #14545.
9. Kalmadi S, Davis M, Dowlati A, et al. Phase I trial of docetaxel, carboplatin and lenalidomide in advanced solid tumors. 2006 ASCO Annual Meeting. Abstract #13027.
10. McNeill G, Kalmadi S, Davis M, et al. Phase II trial of weekly docetaxel and gemcitabine as first-line therapy in advanced NSCLC. 2006 ASCO Annual Meeting. Abstract #17076.
11. Kalmadi S, Wu R, Plasinova M, et al. Pilot study of SELDI-TOF in bone marrow failure syndromes. 2005 ASCO Annual Meeting. Abstract #6547.
12. Tiu R, Kalmadi S, Lowe C, et al. EACA is effective in controlling thrombocytopenic hemorrhage in hematologic malignancies. 2005 ASCO Annual Meeting. Abstract #6648.
13. Kalmadi S, Wu R, Nearman Z, et al. A pilot application of SELDI-TOF mass spectrometry in bone marrow failure syndromes. ASH Annual Meeting 2005. Abstract #3421.
14. Kalmadi S, Mekhail T, Adelstein D, et al. Weekly docetaxel-gemcitabine as first-line treatment in advanced NSCLC: preliminary results of a phase II study. 2004 ASCO Annual Meeting. Abstract #7236.
15. Kalmadi S, Tiu R, Lowe C, et al. EACA reduces transfusion requirements in patients with thrombocytopenic hemorrhage. ASH Annual Meeting 2004. Abstract #3938.

D. Special Presentations

1. "Methods in Clinical Cancer Research." Workshop by ASCO and AACR. Vail, Colorado, 2007.
2. "Utility of SELDI Proteomics in Hematologic Disorders." Poster presentation. AACR Advances in Proteomics in Cancer Research. Key Biscayne, Florida, October 2004.
3. "The Changing Epidemiology and Outcome of Neutropenic Fever." Poster presentation. Resident Research Day, Cleveland Clinic Foundation, May 1999.
4. "Cystic Diseases of the Kidney, from Childhood to Adult Life." Poster presentation. Department of Nephrology Grand Rounds, Cleveland Clinic, April 1998.

XI. EXTRACURRICULAR ACTIVITIES & INTERESTS

Racquetball · Tennis · Chess